8-K: Encompass Health Reaffirms 2024 Financial Guidance at Barclays Healthcare Conference

Encompass Health reiterates its full-year 2024 financial guidance during the Barclays Global Healthcare Conference, maintaining its previously reported revenue, EBITDA, and earnings per share expectations.

Summary

• Encompass Health will participate in the Barclays Global Healthcare Conference in Miami, Florida from March 12-14, 2024.
• The company's President and CEO, Mark Tarr, and CFO, Doug Coltharp, will participate in a fireside chat on March 12, 2024.
• Encompass Health reaffirms its full-year 2024 financial guidance previously reported on February 7, 2024.
• The company expects net operating revenue between $5,200 million and $5,300 million.
• Adjusted EBITDA is projected to be between $1,015 million and $1,055 million.
• Adjusted earnings per share from continuing operations are expected to be between $3.77 and $4.06.
• The company does not provide GAAP guidance due to the unpredictability of certain items.
• However, interest expense and amortization of debt discounts and fees are estimated to be approximately $140 million to $150 million.
• Amortization of debt-related items is estimated to be approximately $10 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company reaffirms its financial guidance, indicating stability and predictability. However, the document also highlights several risks and uncertainties, preventing a higher score.

Positives

• The reaffirmation of the 2024 financial guidance provides stability and predictability for investors.
• The company is actively engaging with the investment community through participation in the Barclays Global Healthcare Conference.
• The company has provided estimates for some GAAP measures, such as interest expense and amortization of debt, which provides additional transparency.

Negatives

• The company does not provide full GAAP guidance due to the unpredictability of certain items, which may make it difficult for investors to fully assess the company's performance.
• The document highlights a number of risks and uncertainties that could impact the company's actual results.

Risks

• An infectious disease outbreak could decrease patient volumes and revenues and lead to staffing and supply shortages.
• Economic downturns, decreased consumer confidence, or capital market instability could impact demand for services.
• Adverse outcomes from lawsuits, claims, and legal or regulatory proceedings could negatively affect the company.
• The company faces risks related to the integration of acquired operations and de novo developments.
• Changes in healthcare regulations and reimbursement policies could impact the company's financial performance.
• Competitive pressures in the healthcare industry could affect the company's market position.
• The company faces challenges in attracting and retaining healthcare professionals.
• General economic conditions and capital market instability could impact the company's performance.
• Increases in the cost of supplies and insurance could negatively affect the company's profitability.

Future Outlook

The company reiterates its full-year 2024 financial guidance, expecting net operating revenue between $5.2 and $5.3 billion, adjusted EBITDA between $1.015 and $1.055 billion, and adjusted earnings per share between $3.77 and $4.06.

Management Comments

• Encompass Health's President and Chief Executive Officer Mark Tarr and Executive Vice President and Chief Financial Officer Doug Coltharp will participate in a fireside chat at the Barclays Global Healthcare Conference.
• The company continues to expect the full-year 2024 ranges as previously reported.

Industry Context

This announcement is consistent with the company's ongoing efforts to communicate its financial outlook to investors and participate in industry events. The healthcare sector is facing various challenges, including regulatory changes and competitive pressures, making consistent guidance important for investor confidence.

Comparison to Industry Standards

• Encompass Health's revenue guidance of $5.2 to $5.3 billion is in line with other large healthcare providers in the rehabilitation sector, such as Select Medical Holdings Corporation (SEM) which reported $6.8 billion in revenue for 2023.
• The adjusted EBITDA guidance of $1.015 to $1.055 billion is comparable to other companies in the sector, although specific comparisons would require a deeper analysis of each company's financial statements and business model.
• The adjusted EPS guidance of $3.77 to $4.06 is within the range of other healthcare companies, but it is important to consider the specific accounting practices and non-GAAP adjustments used by each company.

Stakeholder Impact

• Shareholders will be impacted by the reaffirmation of financial guidance, which provides some certainty about the company's performance.
• Employees may be impacted by the company's ability to attract and retain talent, as well as potential changes in staffing and operating practices.
• Customers may be impacted by the company's ability to provide quality healthcare services, which could be affected by staffing shortages and other challenges.
• Suppliers may be impacted by the company's ability to manage costs and maintain favorable arrangements.
• Creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Encompass Health will participate in the Barclays Global Healthcare Conference from March 12-14, 2024.
• The company's management will participate in a fireside chat on March 12, 2024.

Key Dates

Keywords

Encompass Health, financial guidance, healthcare, EBITDA, revenue, earnings per share, Barclays Global Healthcare Conference, rehabilitation, Medicare, risk factors